Diabetes Care, Vol 21, Issue 8 1246-1249, Copyright © 1998 by American Diabetes Association

ARTICLES

Fasting plasma glucose is a useful test for the detection of gestational diabetes. Brazilian Study of Gestational Diabetes (EBDG) Working Group

AJ Reichelt, ER Spichler, L Branchtein, LB Nucci, LJ Franco and MI Schmidt
Hospital de Clinicas de Porto Alegre, Sao Paulo, Brazil. aajacob@netmarket.com.br

OBJECTIVE: To evaluate fasting plasma glucose as a screening test for states of gestational diabetes. RESEARCH DESIGN AND METHODS: Baseline data of a cohort conducted in general prenatal care units in Brazil, enrolling 5,579 women aged > or = 20 years with gestational ages of 24-28 weeks at the time of testing and no previous diagnosis of diabetes. A standardized 2-h 75-g oral glucose tolerance test was performed in 5,010 women. Gestational diabetes and its subcategories--diabetes and impaired glucose tolerance--were defined according to the 1994 World Health Organization panel recommendations. We evaluated screening properties of calculated sensitivity and specificity for fasting plasma glucose with receiver operator characteristic curves. RESULTS: For detection of the subcategory diabetes, a fasting plasma glucose of 89 mg/dl jointly maximizes sensitivity (88%) and specificity (78%), identifying 22% of the women as test-positive. For detection of impaired glucose tolerance, a value of 85 mg/dl jointly maximizes sensitivity and specificity (68%), identifying as test-positive 35% of the women. Lowering the cut point to 81 mg/dl increases sensitivity to 81%, but decreases specificity to 54%, labeling as test-positive 49% of the women. CONCLUSIONS: Fasting plasma glucose is a useful test for the screening of both subcategories of gestational diabetes, a threshold of 85 mg/dl being an acceptable option. Effective screening for the subcategory diabetes can be achieved using a cut point of 89 mg/dl. If greater emphasis is placed on the detection of impaired glucose tolerance, a lower value, 81 mg/dl, may be needed.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				F.W.F. Hanna, J.R. Peters, J. Harlow, and P.W. Jones Gestational diabetes screening and glycaemic management; National survey on behalf of the Association of British Clinical Diabetologists QJM, October 1, 2008; 101(10): 777 - 784. [Abstract] [Full Text] [PDF]

				R. M.N. Bezerra, V. de Castro, T. Sales, R. Passini Jr, S. T.M. Marba, S. T.O. Saad, and M. J.A. Saad The Gly972Arg Polymorphism in Insulin Receptor Substrate-1 Is Associated With Decreased Birth Weight in a Population-Based Sample of Brazilian Newborns Diabetes Care, March 1, 2002; 25(3): 550 - 553. [Abstract] [Full Text] [PDF]

				L. G. K. de Aguiar, H. J. de Matos, and M. de Brito Gomes Could Fasting Plasma Glucose Be Used for Screening High-Risk Outpatients for Gestational Diabetes Mellitus? Diabetes Care, May 1, 2001; 24(5): 954 - 955. [Full Text]

				D. Perucchini, U. Fischer, G. A Spinas, R. Huch, A. Huch, and R. Lehmann Using fasting plasma glucose concentrations to screen for gestational diabetes mellitus: prospective population based study BMJ, September 25, 1999; 319(7213): 812 - 815. [Abstract] [Full Text]